Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
PCYO Pure Cycle Corp
BACK IMAC Holdings Inc
NYC American Strategic Investment Co
UK Ucommune International Ltd
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
MI Nft Ltd
LAW CS Disco Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

Price
Delayed
$267.03
Day's Change
-2.01 (-0.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
273.61
Day's Low
267.02
Volume
(Light)

Today's volume of 1,119,959 shares is on pace to be much lighter than AMGN's 10-day average volume of 2,723,615 shares.

1,119,959

AMGN's position in the Biotechnology industry

Industry PeersAMGNLLYDHRGILDVRTX

Summary

Company ProfileAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed...
Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products...
Go to LLY summary
Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the...
Go to DHR summary
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral...
Go to GILD summary
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes...
Go to VRTX summary
52-Week Change

VS. INDUSTRY
18.59%
78.87%
-5.87%
21.16%
27.06%
Market Cap

VS. INDUSTRY
$143.9B
$522.1B
$182.6B
$94.1B
$90.8B
Beta

VS. INDUSTRY
0.6
0.3
0.8
0.4
0.5
Dividend Yield

VS. INDUSTRY
3.17%
0.82%
0.44%
3.97%
--
P/E (TTM, GAAP)

VS. INDUSTRY
18.13x
76.42x
29.01x
17.38x
27.19x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$26.6B
$29.5B
$30.4B
$27.4B
$9.5B
Profit Margin

VS. INDUSTRY
30.02%
22.01%
20.95%
19.87%
35.40%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
1.96%
10.08%
25.70%
-13.86%
65.28%
Revenue Growth (TTM)

VS. INDUSTRY
0.75%
1.53%
-1.49%
-0.48%
13.83%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.